Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors from the central anxious system, conolidine modulates alternate molecular targets. A Science Improvements review found that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7,